{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T01:59:21Z","timestamp":1771984761722,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"14","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["3 UH3 DA044831-03S1"],"award-info":[{"award-number":["3 UH3 DA044831-03S1"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["K01 DA55130"],"award-info":[{"award-number":["K01 DA55130"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["K12 HS026370"],"award-info":[{"award-number":["K12 HS026370"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s11606-025-09444-3","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T11:36:04Z","timestamp":1740483364000},"page":"3438-3443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Opioid Treatment Programs and Risks for COVID-19 Infections, Emergency Visits, and Hospitalizations"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8754-995X","authenticated-orcid":false,"given":"Ryan R.","family":"Cook","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kendra L.","family":"Blalock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanae","family":"El Ibrahimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ximena A.","family":"Levander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kacey","family":"Little","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Leichtling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Todd","family":"Korthuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"McCarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"9444_CR1","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3389\/fpsyt.2020.00714","volume":"11","author":"WB Jemberie","year":"2020","unstructured":"Jemberie WB, Stewart Williams J, Eriksson M, et al. Substance use disorders and COVID-19: Multi-faceted problems which require multi-pronged solutions. Front Psychiatry. 2020;11:714.","journal-title":"Front Psychiatry."},{"issue":"1","key":"9444_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.7326\/M20-1141","volume":"173","author":"GC Alexander","year":"2020","unstructured":"Alexander GC, Stoller KB, Haffajee RL, Saloner B. An epidemic in the midst of a pandemic: opioid use disorder and COVID-19. Ann Intern Med. 2020;173(1):57-8.","journal-title":"Ann Intern Med."},{"key":"9444_CR3","unstructured":"Priest KC. The COVID-19 pandemic: practice and policy considerations for patients with opioid use disorder. 2020 [cited 2024 July 3]; Available from: https:\/\/www.healthaffairs.org\/content\/forefront\/covid-19-pandemic-practice-and-policy-considerations-patients-opioid-use-disorder."},{"key":"9444_CR4","unstructured":"Levander XA, Wakeman SE. Covid-19 will worsen the opioid overdose crisis if we don\u2019t prepare now. 2020 [cited 2024 July 3]; Available from: https:\/\/www.statnews.com\/2020\/03\/17\/covid-19-will-worsen-the-opioid-overdose-crisis-if-we-dont-prepare-now\/."},{"issue":"1","key":"9444_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.7326\/M20-1210","volume":"173","author":"WC Becker","year":"2020","unstructured":"Becker WC, Fiellin DA. When epidemics collide: coronavirus disease 2019 (COVID-19) and the opioid crisis. Ann Intern Med. 2020;173(1):59-60.","journal-title":"Ann Intern Med."},{"issue":"9","key":"9444_CR6","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1007\/s10461-020-02887-1","volume":"24","author":"KM Peavy","year":"2020","unstructured":"Peavy KM, Darnton J, Grekin P, et al. Rapid implementation of service delivery changes to mitigate COVID-19 and maintain access to methadone among persons with and at high-risk for HIV in an opioid treatment program. AIDS Behav. 2020;24(9):2469-72.","journal-title":"AIDS Behav."},{"key":"9444_CR7","unstructured":"Substance Use and Mental Health Services Administration. Opioid Treatment Program (OTP) Guidance. 2020 [cited 2024 June 28]; Available from: https:\/\/www.samhsa.gov\/sites\/default\/files\/otp-guidance-20200316.pdf."},{"key":"9444_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4103\/ijpvm.ijpvm_68_22","volume":"13","author":"Z Jamali","year":"2022","unstructured":"Jamali Z, Emamian MH, Hashemi H, Fotouhi A. The association of opioid use disorder and COVID-19, a longitudinal study. Int J Prev Med. 2022;13:157.","journal-title":"Int J Prev Med."},{"issue":"1","key":"9444_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13722-022-00349-8","volume":"17","author":"AH Behnoush","year":"2022","unstructured":"Behnoush AH, Bazmi E, Forouzesh M, Behnoush B. Risk of COVID-19 infection and the associated hospitalization, ICU admission and mortality in opioid use disorder: a systematic review and meta-analysis. Addict Sci Clin Pract. 2022;17(1):68.","journal-title":"Addict Sci Clin Pract."},{"issue":"5","key":"9444_CR10","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1111\/add.16105","volume":"118","author":"N Krawczyk","year":"2023","unstructured":"Krawczyk N, Rivera BD, Basaraba C, et al. COVID-19 complications among patients with opioid use disorder: a retrospective cohort study across five major NYC hospital systems. Addiction. 2023;118(5):857-69.","journal-title":"Addiction."},{"issue":"6","key":"9444_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","volume":"47","author":"O Amram","year":"2021","unstructured":"Amram O, Amiri S, Panwala V, Lutz R, Joudrey PJ, Socias E. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era. Am J Drug Alcohol Abuse. 2021;47(6):722-9.","journal-title":"Am J Drug Alcohol Abuse."},{"issue":"1","key":"9444_CR12","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13011-023-00564-9","volume":"18","author":"A Adams","year":"2023","unstructured":"Adams A, Blawatt S, Magel T, et al. The impact of relaxing restrictions on take-home doses during the COVID-19 pandemic on program effectiveness and client experiences in opioid agonist treatment: a mixed methods systematic review. Subst Abuse Treat Prev Policy. 2023;18(1):56.","journal-title":"Subst Abuse Treat Prev Policy."},{"key":"9444_CR13","doi-asserted-by":"publisher","first-page":"108801","DOI":"10.1016\/j.jsat.2022.108801","volume":"141","author":"KA Hoffman","year":"2022","unstructured":"Hoffman KA, Foot C, Levander XA, et al. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis. J Subst Abuse Treat. 2022;141:108801.","journal-title":"J Subst Abuse Treat."},{"issue":"5","key":"9444_CR14","doi-asserted-by":"publisher","first-page":"e2314328","DOI":"10.1001\/jamanetworkopen.2023.14328","volume":"6","author":"EA Taylor","year":"2023","unstructured":"Taylor EA, Cantor JH, Bradford AC, Simon K, Stein BD. Trends in methadone dispensing for opioid use disorder after medicare payment policy changes. JAMA Netw Open. 2023;6(5):e2314328.","journal-title":"JAMA Netw Open."},{"issue":"3","key":"9444_CR15","doi-asserted-by":"publisher","first-page":"e238","DOI":"10.1016\/S2468-2667(23)00023-3","volume":"8","author":"N Krawczyk","year":"2023","unstructured":"Krawczyk N, Rivera BD, Levin E, Dooling BCE. Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy. Lancet Public Health. 2023;8(3):e238-e46.","journal-title":"Lancet Public Health."},{"key":"9444_CR16","first-page":"100195","volume":"12","author":"S Naher","year":"2024","unstructured":"Naher S, Pervez S, Ahmed F, Elijah O, Mahmud MT, Saif-Ur-Rahman KM. Effectiveness of take-home methadone treatment among patients with opioid use disorders during COVID-19: A systematic review. Health Sci Rev. 2024;12:100195","journal-title":"Health Sci Rev."},{"key":"9444_CR17","unstructured":"Department of Health and Human Services. Medications for the Treatment of Opioid Use Disorder. 2024 [cited 2024 June 28]; Available from: https:\/\/www.govinfo.gov\/content\/pkg\/FR-2024-02-02\/pdf\/2024-01693.pdf."},{"key":"9444_CR18","unstructured":"Oregon Health Authority. Oregon Access Monitoring Review Plan. 2016 [cited 2025 January 20]; Available from: https:\/\/www.medicaid.gov\/medicaid\/access-care\/downloads\/or-amrp-16.pdf."},{"issue":"1","key":"9444_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13722-019-0160-6","volume":"14","author":"D McCarty","year":"2019","unstructured":"McCarty D, Gu Y, McIlveen JW, Lind BK. Medicaid expansion and treatment for opioid use disorders in Oregon: an interrupted time-series analysis. Addict Sci Clin Pract. 2019;14(1):31.","journal-title":"Addict Sci Clin Pract."},{"issue":"9","key":"9444_CR20","doi-asserted-by":"publisher","first-page":"e1003321","DOI":"10.1371\/journal.pmed.1003321","volume":"17","author":"SL Harrison","year":"2020","unstructured":"Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis. PLoS Med. 2020;17(9):e1003321.","journal-title":"PLoS Med."},{"key":"9444_CR21","doi-asserted-by":"publisher","first-page":"E66","DOI":"10.5888\/pcd18.210123","volume":"18","author":"L Kompaniyets","year":"2021","unstructured":"Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020-March 2021. Prev Chronic Dis. 2021;18:E66.","journal-title":"Prev Chronic Dis."},{"issue":"1","key":"9444_CR22","doi-asserted-by":"publisher","first-page":"19","DOI":"10.15585\/mmwr.mm7101a4","volume":"71","author":"C Yek","year":"2022","unstructured":"Yek C, Warner S, Wiltz JL et al. Risk factors for severe COVID-19 outcomes among persons aged >\/=18 years who completed a primary COVID-19 Vaccination Series - 465 Health Care Facilities, United States, December 2020-October 2021. MMWR Morb Mortal Wkly Rep. 2022;71(1):19\u201325","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"2","key":"9444_CR23","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/all.14657","volume":"76","author":"YD Gao","year":"2021","unstructured":"Gao YD, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428-55.","journal-title":"Allergy."},{"key":"9444_CR24","unstructured":"Centers for Disease Control and Prevention. Science Brief: Evidence Used to Update the List of Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19. Updated June 15, 2022. Available at https:\/\/wwwcdcgov\/coronavirus\/2019-ncov\/science\/science-briefs\/underlying-evidence-tablehtml Accessed September 13, 2022. 2022."},{"key":"9444_CR25","unstructured":"Gasparini A, Salmasian H, Williman J, Chia SY, Teo E. comorbidity: Computing Comorbidity Scores. 2023 [cited 2024 June 28]; Available from: https:\/\/cran.r-project.org\/web\/packages\/comorbidity\/index.html."},{"issue":"6","key":"9444_CR26","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/ADM.0000000000000812","volume":"15","author":"JW McIlveen","year":"2021","unstructured":"McIlveen JW, Hoffman K, Priest KC, Choi D, Korthuis PT, McCarty D. Reduction in oregon\u2019s medication dosing visits after the SARS-CoV-2 relaxation of restrictions on take-home medication. J Addict Med. 2021;15(6):516-8.","journal-title":"J Addict Med."},{"issue":"1","key":"9444_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13722-021-00275-1","volume":"16","author":"N Krawczyk","year":"2021","unstructured":"Krawczyk N, Fawole A, Yang J, Tofighi B. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. Addict Sci Clin Pract. 2021;16(1):68.","journal-title":"Addict Sci Clin Pract."},{"issue":"1","key":"9444_CR28","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s12913-022-07832-7","volume":"22","author":"S Bandara","year":"2022","unstructured":"Bandara S, Maniates H, Hulsey E, et al. Opioid treatment program safety measures during the COVID-19 pandemic: a statewide survey. BMC Health Serv Res. 2022;22(1):418.","journal-title":"BMC Health Serv Res."},{"issue":"7","key":"9444_CR29","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1016\/j.pec.2022.03.006","volume":"105","author":"AW Kang","year":"2022","unstructured":"Kang AW, DeBritz AA, Hoadley A, et al. Barriers and poor telephone counseling experiences among patients receiving medication for opioid use disorders. Patient Educ Couns. 2022;105(7):2607-10.","journal-title":"Patient Educ Couns."},{"issue":"3","key":"9444_CR30","doi-asserted-by":"publisher","first-page":"100559","DOI":"10.1016\/j.hjdsi.2021.100559","volume":"9","author":"R Sokol","year":"2021","unstructured":"Sokol R, Suter S, Pierce B, et al. A novel transition: Lessons learned during rapid implementation and evolution of telehealth group based opioid treatment (t-GBOT) during the COVID-19 pandemic. Healthc (Amst). 2021;9(3):100559.","journal-title":"Healthc (Amst)."},{"key":"9444_CR31","doi-asserted-by":"crossref","unstructured":"Krawczyk N, Rivera BD, King C, Dooling BCE. Pandemic telehealth flexibilities for buprenorphine treatment: a synthesis of evidence and policy implications for expanding opioid use disorder care in the United States. Health Aff Sch. 2023;1(1):qxad013.","DOI":"10.1093\/haschl\/qxad013"},{"issue":"1","key":"9444_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13722-021-00281-3","volume":"16","author":"XA Levander","year":"2021","unstructured":"Levander XA, Hoffman KA, McIlveen JW, McCarty D, Terashima JP, Korthuis PT. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis. Addict Sci Clin Pract. 2021;16(1):72.","journal-title":"Addict Sci Clin Pract."},{"key":"9444_CR33","unstructured":"Oregon Health Authority. Covid-19 2020 Report. 2020 [cited 2020 June 28]; Available from: https:\/\/www.oregon.gov\/oha\/covid19\/Documents\/DataReports\/2020-COVID-19-Data-Review-Re-Issue.pdf."},{"key":"9444_CR34","unstructured":"Oregon Health Authority. Covid-19 2021 Report. 2021 [cited 2024 June 28]; Available from: https:\/\/www.oregon.gov\/oha\/covid19\/Documents\/DataReports\/2021-Annual-Data-Report.pdf."},{"issue":"13","key":"9444_CR35","doi-asserted-by":"publisher","first-page":"489","DOI":"10.15585\/mmwr.mm7113e1","volume":"71","author":"B Rader","year":"2022","unstructured":"Rader B, Gertz A, Iuliano AD, et al. Use of At-Home COVID-19 Tests - United States, August 23, 2021-March 12, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(13):489-94.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"9444_CR36","doi-asserted-by":"publisher","first-page":"103127","DOI":"10.1016\/j.drugpo.2021.103127","volume":"92","author":"C Zolopa","year":"2021","unstructured":"Zolopa C, Hoj S, Bruneau J, et al. A rapid review of the impacts of \u201cBig Events \u201d on risks, harms, and service delivery among people who use drugs: Implications for responding to COVID-19. Int J Drug Policy. 2021;92:103127.","journal-title":"Int J Drug Policy."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09444-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-025-09444-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-025-09444-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T01:05:20Z","timestamp":1771981520000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-025-09444-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":36,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["9444"],"URL":"https:\/\/doi.org\/10.1007\/s11606-025-09444-3","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations:"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest:"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}